Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH009 in Advanced Head and Neck Squamous and Ovarian Cancer
NCT06232863Phase 1Recruiting
- Sponsor
- Zhuhai Beihai Biotech
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Modality
- Albumin, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of beizray in head and neck squamous cell carcinoma (HNSCC) and ovarian carcinoma, sponsored by Zhuhai Beihai Biotech. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Recommended Phase 2 Dose and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
beizray
03
Conditions
head and neck squamous cell carcinoma (HNSCC)ovarian carcinoma
Beyond the preview
Go deeper on NCT06232863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232863.